Evidence map›Paper›PMID 34104584›Full record

ReviewCureus2021

HIV-Associated Anal Cancer.

Pushti Khandwala, Sachi Singhal, Devashish Desai, Meghana Parsi, Rashmika Potdar

Open access · diamondAbstract readReview
In one paragraph

Review in Cureus, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 17 citations in OpenAlex.

  1. Review
  2. Short-term efficacy and safety of COFrontiers in medicine · 2026
    Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Factors Influencing Outcomes and Survival in Anal Cancer.Current oncology (Toronto, Ont.) · 2024
    Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Pushti KhandwalaInternal Medicine, Crozer Keystone Health System, Upland, USA.
Sachi SinghalInternal Medicine, Crozer Keystone Health System, Upland, USA.
Devashish DesaiInternal Medicine, Crozer Keystone Health System, Upland, USA.
Meghana ParsiInternal Medicine, Crozer Keystone Heath System, Upland, USA.
Rashmika PotdarHematology and Medical Oncology, Crozer Keystone Health System, Upland, USA.
Crozer-Keystone Health System · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Anal cancer, despite being a rare malignancy, is increasing in incidence, accounting for 0.5% of all new cancer cases in the United States, with rate of new cases being 1.9 per 100,000 men and women. It is common in immunocompromised individuals, especially those with malignancy, human immunodeficiency virus (HIV) and human papillomavirus (HPV) infection. Despite similar treatment of anal cancer in both HIV-positive and negative patients, guidelines for prevention and treatment of therapy-related side effects are rarely studied. While these patients have a better prognosis on HAART, limited guidelines exist regarding appropriate therapy. There is a common link between HPV and HIV and the transmission of one is associated with increased risk of transmission of the other. HPV vaccine which is known to prevent high-grade cervical intraepithelial neoplasia is thought to also decrease the incidence of anal intraepithelial neoplasia. The association of HPV vaccine in the prevention of anal cancer in high-risk groups with HIV is a scarcely studied subject that requires further research.

Indexed as

anal cancerhivhpvhpv vaccine

Identifiers

PMID34104584
PMCPMC8174397
OpenAlexW3158198239

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.